ASCO 2024 | Intra-treatment hypoxia directed major radiation de-escalation as definitive treatment for HPV+ OC

Shloma Koyfman • 3 Jun 2024

ASCO 2024

Head and Neck Cancer

Shloma Koyfman, MD, Cleveland Clinic, Cleveland, OH, discusses the outcomes of a multi-center Phase II trial investigating hypoxia-directed de-escalated chemoradiotherapy without surgery for human papillomavirus associated oropharyngeal carcinoma (HPV+ OPC). With 150 eligible patients, de-escalation to 30Gy based on hypoxia status achieved notable toxicity reduction while maintaining a 2-year locoregional control of 95% and a 2-year overall survival probability of 99%. These findings support chemoradiation without surgery as an effective treatment approach for HPV+ OPC. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.